Investment Thesis
I first learned of remestemcel-l (labeled Prochymal at that time) over 10 years ago, I remember my response well, new products take years! But I followed Osiris Therapeutics in its development. This lead me to Mesoblast after it acquired remestemcel-l and associated intellectual property from Osiris Therapeutics in 2013.
Mesoblast has been methodically working to develop regenerative medical products since its founding in 2004. MESO leverages mesenchymal lineage cells to respond to signals, tame inflammation, and stimulate regeneration. Stem cells have had a challenge in getting approved in the US. Yet Meso is